智通财经APP讯，中国一重(601106.SH)发布风险提示公告称，公司被列入"可控核聚变"概念股。截至目 前，公司仅承接极少量相关配件项目，且相关产品尚未形成收入。 ...

中国一重（601106）(601106.SH)发布风险提示公告称，公司被列入"可控核聚变"概念股。截至目前， 公司仅承接极少量相关配件项目，且相关产品尚未形成收入。 ...

本周主力资金净流出光模块和商业航天概念股。 今日（1月9日），A股全天震荡走强。截至收盘，上证指数涨0.92%，日K线16连阳，站上4100点关 口，最新报4120.43点。深证成指涨1.15%，创业板指涨0.77%。市场全天成交31523.68亿元，较昨日大 幅放量3260.66亿元。 | 行情 | 资金净流入 | 涨跌分布 | | --- | --- | --- | | 上证指数 | 深证成指 | 科创综指 | | 4120.43 | 14120.15 | 1803.40 | | +37.45 +0.92% +160.67 +1.15% +36.83 +2.09% | | | | 万得全A | 创业板指 | 北证50 | | 6737.75 | 3327.81 | 1524.26 | | +78.53 +1.18% +25.51 +0.77% +15.89 +1.05% | | | | 沪深300 | 中证500 | 中证A500 | | 4758.92 | 8056.69 | 5881.95 | | +21.27 +0.45% +162.14 +2.05% +51.38 +0.88% | | | | 中 ...

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

A股的"开门红"行情再上一个台阶。1月9日，沪指盘中突破4100点，创十年新高，两市成交额时隔近四 个月突破3万亿元。 截至9日收盘，上证指数报收4120.43点，涨0.92%；深成指和创业板指分别报收14120.15点和3327.81 点，涨幅1.15%和0.77%。两市成交额达到3.12万亿元，较前一交易日放量3224亿元。 当天盘面上，市场热点快速轮动，全市场超3900只个股上涨，AI应用概念集体爆发，易点天下20CM涨 停，利欧股份、浙文互联等涨停。同时，商业航天、可控核聚变等概念延续强势；下跌方面，脑机接口 概念下挫，美好医疗、倍益康跌超10%。 2026年开年至今，沪指已连续5个交易日（1月5日至9日）收于4000点上方，其中4个交易日收涨，仅在1 月8日微跌0.07%。 "市场在快速上行过程中，也显现出一些值得关注的现象。"华鑫证券首席策略分析师严凯文告诉第一财 经，目前两市日均成交额维持在2.5万亿元以上，换手率显著上升，表明市场交投情绪较为活跃。 从9日当天情况看，多股换手率亮眼。其中，邵阳液压换手率达到58.67%，较前一交易日（19.75%）大 幅提升；雪人集团、华凌线缆当日换手率也均超 ...

中国一重1月9日公告，公司股票交易连续三个交易日内日收盘价格涨幅偏离值累计超过20%。2026年1 月9日，公司当日股票再次以涨停价收盘。公司被列入"可控核聚变"概念股。截至目前，公司仅承接极 少量相关配件项目，且相关产品尚未形成收入。公司股票剔除大盘整体影响后的实际波动幅度较大，敬 请广大投资者注意二级市场交易风险，理性决策，审慎投资。 ...

Core Viewpoint - The military industry is experiencing a significant surge, with the military ETF Huabao (512810) showing strong performance as 73 out of 80 constituent stocks rose, and several stocks hitting historical highs [1][9]. Group 1: Market Performance - The military ETF Huabao (512810) opened high and surged over 5.5% during the day, closing up 3.91%, marking four consecutive days of record highs [10]. - The ETF recorded a trading volume of 1.32 billion yuan, the highest in nearly a month, and has seen a steep increase of 13.57% this week, significantly outperforming major indices like the Shanghai Composite Index (+3.82%) and the ChiNext Index (+3.89%) [10][12]. Group 2: Stock Highlights - Notable stocks within the ETF include: - DanGao Technology (688270) with a price increase of 19.00% and a trading volume of 6.128 billion yuan [2]. - Huatai Technology (688281) up by 18.92% with a trading volume of 0.886 billion yuan [2]. - Guocai Zhugong (688543) rising 18.01% with a trading volume of 2.293 billion yuan [2]. - Other significant performers include Guobo Electronics, Western Superconducting, and Aerospace Electronics, all achieving substantial gains [1][10]. Group 3: Catalysts for Growth - The booming military market is driven by multiple factors, including the ongoing development of commercial aerospace under the "Aerospace Power" strategy, which is expected to see the commercial aerospace industry in China reach a scale of 8 trillion yuan by 2030 [4][12]. - The military ETF Huabao (512810) includes 24 commercial aerospace concept stocks, accounting for over 32% of its total weight [4][12]. Group 4: Global Defense Spending Trends - Recent geopolitical developments, such as U.S. President Trump's proposal to increase the U.S. military budget from 1 trillion to 1.5 trillion dollars for the fiscal year 2027, reflect a growing trend of increased defense budgets in the U.S., EU, and Japan, indicating rising complexities and uncertainties in international security [12][14]. - Analysts predict that global military trade demand will continue to grow, with China's military trade market share currently at 5.87%, significantly lower than the U.S. share of 42.64% [6][14].

每经AI快讯，1月9日，中国一重(601106.SH)公告称，公司股票交易于1月6日、1月7日、1月8日连续三 个交易日内日收盘价格涨幅偏离值累计超过20%。1月9日，公司当日股票再次以涨停价收盘。公司被列 入"可控核聚变"概念股。截至目前，公司仅承接极少量相关配件项目，且相关产品尚未形成收入。公司 股票剔除大盘整体影响后的实际波动幅度较大，敬请广大投资者注意二级市场交易风险，理性决策，审 慎投资。 ...

人民财讯1月9日电，中国一重（601106）1月9日公告，公司股票交易于2026年1月6日、2026年1月7日、 2026年1月8日连续三个交易日内日收盘价格涨幅偏离值累计超过20%。公司被列入"可控核聚变"概念 股。截至目前，公司仅承接极少量相关配件项目，且相关产品尚未形成收入。 ...

Group 1 - The company is exploring the application of its lithium isotope separation technology in the nuclear power sector, particularly in relation to the construction of the world's first controllable nuclear fusion commercial demonstration reactor [1] - The company's lithium isotope enrichment technology is considered a key functional material in the nuclear power field [1] - The company plans to expand into the nuclear power sector in accordance with market demand principles [1]